Trials / Completed
CompletedNCT02124668
A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
A Phase 2, Multicenter, Single-arm, Open Label Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Astellas Pharma Europe B.V. · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to monitor the safety of enzalutamide in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enzalutamide | oral |
Timeline
- Start date
- 2014-09-23
- Primary completion
- 2017-05-25
- Completion
- 2017-05-25
- First posted
- 2014-04-28
- Last updated
- 2024-11-21
Locations
4 sites across 2 countries: Georgia, Russia
Source: ClinicalTrials.gov record NCT02124668. Inclusion in this directory is not an endorsement.